In Type 1 diabetes patients treated with teplizumab, responders showed a population of CD8 memory T cells that expressed EOMES and inhibitory receptors and retained some effector function as shown by IFNG and GZB expression, like the DP T cells in this study (51). Here, CD8A is linked to type 1 diabetes mellitus.